Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 243-251

  Fedele, Palma ^a   Calvani, Nicola ^a   Marino, Antonella ^a   Orlando, Laura ^a   Schiavone, Paola ^a   Quaranta, Annamaria ^a   Cinieri, Saverio ^a,b  

^a A Perrino Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Endocrine resistance; Endocrine therapy; Metastatic breast cancer; Targeted agents

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GANITUMAB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; VORINOSTAT;

ADVANCED CANCER; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HYPERGLYCEMIA; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84867891436     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.004     Document Type: Review

References (75)

1. Chen W.Y., Colditz G.A. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007, 4(July (7)):415-423.
2. Bernstein L., Lacey J.V. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?. J Natl Cancer Inst 2011, 103(March (6)):470-477.
3. Bartlett J.M., Brookes C.L., Robson T., et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011, 29(April (12)):1531-1538. [Epub 2011 March 21].
4. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62(February):233-247. [Review].
5. Eroles P., Bosch A., Bermejo B., et al. Mechanisms of resistance to hormonal treatment in breast cancer. Clin Transl Oncol 2010, 12(April (4)):246-252. [Review].
6. Pancholi S., Lykkesfeldt A.E., Hilmi C., et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 2008, 15(December (4)):985-1002. [Epub 2008 September 29].
7. Knowlden J.M., Hutcheson I.R., Jones H.E., et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
8. Nicholson R.I., Hutcheson I.R., Britton D., et al. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 2005, 93(February (2-5)):257-262. [Review].
9. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000, 18:3172-3186.
10. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000, 74(November (5)):279-285.
11. Skafar D.F., Koide S. Understanding the human estrogen receptor-alpha using targeted mutagenesis. Mol Cell Endocrinol 2006, 246(February (1-2)):83-90. [Epub 2006 January 18].
12. Ogawa S., Inoue S., Watanabe T., et al. The complete primary structure of human estrogen receptor beta (hER-beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998, 243:122-126.
13. Kumar V., Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988, 55:145-156.
14. Hayes E., Nicholson R.I., Hiscox S. Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci 2011, 16(January):838-848. [Review].
15. Arpino G., Weichmann L., Osborne C.K., et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev 2008, 29:217-233.
16. Aguilar H., Solé X., Bonifaci N., et al. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29(November (45)):6071-6083. [Epub 2010 August 16].
17. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine esistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
18. Chen D., Washbrook E., Sarwar N., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002, 21:4921-4931.
19. Dowsett M., Johnston S., Martin L.A., et al. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer 2005, 12(Suppl. 1):S113-S117.
20. Hu J.C., Mokbel K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?. Eur J Surg Oncol 2001, 27:335-337.
21. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
22. Nicholson R.I., McClelland R.A., Finlay P., et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993, 7:1018-1023.
23. Archer S.G., Eliopoulos A., Spandidos D., et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995, 72:1259-1266.
24. Stotter A., Walker R. Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study. Crit Rev Oncol Hematol 2010, 75(September (3)):249-256. [Epub 2009 December 6].
25. Arpino G., Green S.J., Allred D.C., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004, 10:5670-5676.
26. Mueller H., Flury N., Eppenberger-Castori S., et al. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000, 89:384-388.
27. Nicholson R.I., McClelland R.A., Gee J.M.W., et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 2000, 29:117-125.
28. Miller D.L., El-Ashry D., Cheville A.L., et al. Emergence of MCF7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 1994, 5:1263-1274.
29. El-Zarruk A.A., van den Berg H.W. The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett 1999, 142:185-219.
30. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(November (33)):5529-5537. [Epub 2009 September 28].
31. Osborne C.K., Neven P., Dirix L.Y., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17(March (5)):1147-1159.
32. Cristofanilli M., Valero V., Mangalik A., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. J Clin Cancer Res 2010, 16(March (6)):1904-1914.
33. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(November (33)):5538-5546.
34. Massarweh S., Osborne C.K., Creighton C.J., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68(February (3)):826-833.
35. Moulder S.L., Yakes F.M., Muthuswamy S.K., et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61:8887-8895.
36. Mita M., de Bono J.S., Patnaik A., et al. A phase II and biologic correlative study investigating anastrozole in combination with gefitinib in post menopausal patients with estrogen receptor positive metastatic breast carcinoma who have previously failed hormonal therapy. Breast Cancer Res Treat 2005, 94(Suppl. 1). [Abstract 1117].
37. Dowsett M., Smith I., Skene A., et al. Biological and clinical outcomes from a phase II placebo controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer. Proc Am Soc Clin Oncol 2006, 24(Suppl. 18). [Abstract 515].
38. Polychronis A., Sinnett H.D., Hadjiminas D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomized trial. Lancet Oncol 2005, 6:383-391.
39. Curran M.P. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. Drugs 2010, 70(July (11)):1411-1422.
40. Konecny G.E., Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
41. Press M.F., Finn R.S., Cameron D., et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008, 14:7861-7870.
42. Leary A.F., Drury S., Detre S., et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16(March (5)):1486-1497.
43. Kraus M.H., Popescu N.C., Amsbaugh S.C., et al. Overexpression of the EGF receptor related proto-oncogene erbB2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987, 6:605-610.
44. Curigliano G., Bagnardi V., Viale, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011, 22(October (10)):2227-2233. [Epub 2011 February 22].
45. Schmelzle T., Hall M. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
46. Jefferies H., Fumagalli S., Dennis P.B. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997, 16:3693-3704.
47. Gingras A., Gygi S., Raught B. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999, 13:1422-1437.
48. Di Cosimo S., Scaltriti M., Val D. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. J Clin Oncol 2007, 25(Suppl. 18):3511.
49. Rudolf J., Boulay A., Zumstein-Mecker S., Evans D.B., O'Reilly T., Lane H.A. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001with the aromatase inhibitor letrozole in breast carcinomas. Proc Am Assoc Cancer Res 2004, 45:A5619.
50. DeGraffenried L.A., Friedrichs W.E., Russel D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004, 10:8059-8067.
51. Baselga J., Fumoleau P., Gil M. Phase II, 3 arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Preliminary results. J Clin Oncol 2004, 22(Suppl. 14):544.
52. Chow L.W.S., Sun Y., Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl. 1):6091.
53. Baselga J., Semiglazov V., Van Dam P. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637.
54. Baselga J, Campone M, Sahmoud T, et al. 2011 European Multidisciplinary Cancer Congress (EMCC): Abstract 9LBA.
55. Bachelot T, Bourgier C., Cropet C., et al. SABCS 2010. Abstract S1-6.
56. Miller T.W., Hennessy B.T., Gonzalez-Angulo A.M., et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413.
57. Fan M., Yan P.S., Hartman-Frey C., et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006, 66:11954-11966.
58. Campbell R.A., Bhat-Nakshatri P., Patel N.M., et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824.
59. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
60. Sanchez C., Ma X.C., Crowder R., et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011, 13:R21.
61. Reid G., Metivier R., Lin C.Y., et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005, 24:4894-4907.
62. Hirokawa Y., Arnold M., Nakajima H., et al. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 2005, 4(9):956-960.
63. Jang E.R., Lim S.J., Lee E.S., et al. The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2004, 23(9):1724-1736.
64. Duong V., Licznar A., Margueron R., et al. ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25(12):1799-1806.
65. Munster P.N., Thurn K.T., Thomas S., et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104(June (12)):1828-1835.
66. Summy J.M., Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metast Rev 2003, 22:337-358.
67. Frame M.C. Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 2002, 1602:114-130.
68. Yue W., Fan P., Wang J., et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007, 106:102-110.
69. Morgan L., Gee J., Pumford S., et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 2009, 8(6):1550-1558.
70. Roudabush F.L., Pierce K.L., Maudsley S., Khan K.D., Luttrell L.M. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000, 275:22583-22589.
71. Westley B.R., Clayton S.J., Daws M.R., et al. Interactions between the oestrogen and insulin-like growth factor signaling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 1998, 63:35-44.
72. Lanzino M., Morelli C., Garofalo, et al. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 2008, 8(November (7)):597-610. [Review].
73. Tolcher A.W., Rothenberg M.L., Rodon J., et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007, 25(18S):3002.
74. Sarantopoulos J., Mita A.C., Mulay M., et al. Safety and pharmacokinetics of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab or gemcitabine. J Clin Oncol 2008, 26(15S):3583.
75. Kaufman PA, Ferrero JM, Bourgeois H, et al. SABCS 2010. Abstract S1-4.